Eli Lilly Widens Lead Over Novo Nordisk in Obesity Drug Market

The gap between Eli Lilly and Novo Nordisk is expanding after their recent earnings reports, with Lilly strengthening its position in the obesity treatment race while Novo Nordisk works to regain market share.

6 Aug, 13:45 — 6 Aug, 13:45

Post Share

Sources

Showing 1 of 1 sources

cnbcMostly Factual4d ago

The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings

As Lilly widens its lead in the obesity race, Novo is still racing to win back market share and restore investor confidence in its pipeline.

Read full article →

PERSPECTA

PERSPECTA

Eli Lilly Widens Lead Over Novo Nordisk in Obesity Drug Market

Sources

The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings

Related Stories

CPP Investments to Acquire Stake in Two Hilton Hotels in Brazil

Fuel Prices Drop in North Macedonia

Poland Changes Tax Interpretation for Foreign Branch Accounting

Eli Lilly's Foundayo Approved in UK, Expanding Global Weight-Loss Market Battle

PERSPECTA